<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30055521</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>24</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-8198</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>36</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Annals of diagnostic pathology</Title>                <ISOAbbreviation>Ann Diagn Pathol</ISOAbbreviation>            </Journal>            <ArticleTitle>Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>28-30</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S1092-9134(18)30185-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.anndiagpath.2018.06.003</ELocationID>            <Abstract>                <AbstractText>Risk-reducing salpingo-oophorectomy (RRSO) is a procedure to reduce the risk of adnexal cancer in BRCA mutation carriers and for hormonal manipulation in women with breast cancer (BC). The goal of the study is to report the frequency of subsequent BC and high-grade serous carcinoma (HGSC) following RRSO in BRCA1 and BRCA2 mutation carriers and in patients with personal history of BC with or without BRCA mutation. A series of 147 consecutive patients who received a RRSO were reviewed. Patient's age, clinical history, BC histotype, gene mutation data, incidence of post-RRSO BC and HGSC and time intervals were analyzed. The cases were followed for a mean of 49 months. Group 1 consists of 97 cases with pathogenic or likely pathogenic &quot;deleterious&quot; mutation BRCA1 (n = 49) or BRCA2 (n = 48). Group 2 consists of 50 cases with history of BC and no documented BRCA gene mutation. Prior to RRSO, 42 (43%) cases in group 1 had a history of BC and all cases in group 2 had a history of BC. There was no difference between the groups in the age at diagnosis for BC (Mean of 44 years). Following RRSO, 2/49 cases (4%) with BRCA1 mutation were found to have occult HGSC and none in BRCA2 cases. There were also 1 BC recurrence and 1 primary BC with BRCA1 mutation compared to 5 recurrent BC in Group 2 (10%). In conclusion, the risk of subsequent recurrent BC after RRSO appears to be higher (10%) in patients with history of BC with no BRCA mutation when compared to (2%) in BRCA mutation carriers.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Straub</LastName>                    <ForeName>Melissa M</ForeName>                    <Initials>MM</Initials>                    <AffiliationInfo>                        <Affiliation>Vanderbilt University, Department of Pathology, Microbiology and Immunology, Nashville, TN, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Podoll</LastName>                    <ForeName>Mirna B</ForeName>                    <Initials>MB</Initials>                    <AffiliationInfo>                        <Affiliation>Vanderbilt University, Department of Pathology, Microbiology and Immunology, Nashville, TN, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>David</LastName>                    <ForeName>Stephanie N</ForeName>                    <Initials>SN</Initials>                    <AffiliationInfo>                        <Affiliation>Vanderbilt University, Department of Pathology, Microbiology and Immunology, Nashville, TN, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wiesner</LastName>                    <ForeName>Georgia L</ForeName>                    <Initials>GL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Desouki</LastName>                    <ForeName>Mohamed M</ForeName>                    <Initials>MM</Initials>                    <AffiliationInfo>                        <Affiliation>Vanderbilt University, Department of Pathology, Microbiology and Immunology, Nashville, TN, USA. Electronic address: mokhtar.desouki@vanderbilt.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>06</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Ann Diagn Pathol</MedlineTA>            <NlmUniqueID>9800503</NlmUniqueID>            <ISSNLinking>1092-9134</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BRCA</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Mutation</Keyword>            <Keyword MajorTopicYN="N">Ovarian cancer</Keyword>            <Keyword MajorTopicYN="N">Risk-reducing salpingo-oophorectomy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30055521</ArticleId>            <ArticleId IdType="pii">S1092-9134(18)30185-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.anndiagpath.2018.06.003</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>